$10M Rev, Growing Wound Care Medical Group

XYWC1F - $10 Million Revenue, Fast Growing Wound Care Medical Group (MSO) Seeking Strategic or a Capital Partner

Company Overview
Broker is proud to be the exclusive representative of a leading, physician-founded, multispecialty chronic-care platform operating as an MSO (Medical Service Organization Model) in the Southwestern United States. The group is seeking a strategic or capital partner to accelerate its next phase of expansion through targeted acquisitions and new de-novo centers. With nearly two decades of operating history, the company has built one of the most comprehensive and payer-integrated wound care and vascular management platforms in the region, offering an exceptional opportunity for investors seeking exposure to the fastest-growing sectors in healthcare—chronic disease management, diabetic care, and limb preservation.

The company currently operates multiple state-of-the-art outpatient facilities and a fully equipped vascular and vein lab, delivering an integrated continuum of care that includes wound management, infectious disease, podiatry, endocrinology, and vascular surgery. Its model is designed around patient outcomes and cost reduction, with services extending into home-based wound care and DME supply delivery in the near future, to ensure continuity across the patient journey. The result is a scalable, diversified platform with recurring revenue streams across outpatient, procedural, and home-care verticals.

Financial Performance and Growth Trajectory
Over the past three years, the company’s revenue has grown from approximately $7.2 million in 2022 to $10.8 million in 2024, reflecting a compound annual growth rate (CAGR) exceeding 20%. The management projects a $10 million revenue in 2025 but a temporary and a significant drop in EBITDA this year due to various investments and expansion activities.

Forecasted 2025–2026 Projection
Based on prior three-year revenue CAGR of ~22% and normalization of 2025 YTD variances (seasonality and recent expansion costs), full-year 2025 revenue is projected at $10 million, with an EBITDA recovery in 2026 to $2.4–$2.6 million.

2026 projections incorporate expected stabilization of the newly opened facility and added vascular volume, and are estimated to be:

Revenue: ~$12.0–$12.5 million
EBITDA: ~$2.4–$2.6 million
EBITDA Margin: ~20–21%
Expansion Opportunities
The company is poised for both horizontal and vertical expansion. Immediate targets include:

Regional roll-ups of podiatry and home-health groups to consolidate chronic-care services under one unified payer structure.
Launch of new de-novo centers in underserved diabetic and vascular markets in other locations as well as neighboring states.
Addition of IV infusion services and a 340B pharmacy program, enhancing recurring revenue potential.
Pursuit of an Ambulatory Surgical Center (ASC) license to elevate procedural capacity and margin capture.
This strategy aims to replicate the company’s successful regional model and scale it to a multi-state chronic-care platform spanning 15–20 locations across 4–5 states within five to seven years.